Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Zelman & Assoc Initiates Coverage On Ferguson with Buy Rating

Zelman & Assoc Initiates Coverage On Ferguson with Buy Rating

Zelman & Assoc initiates coverage on Ferguson (NYSE:FERG) with a Buy rating.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Zelman & Assoc initiates coverage on Ferguson (NYSE:FERG) with a Buy rating.

PDS Biotech Posts 100% Clinical Response In Cervical Cancer Patients For Its Lead Program

By Vandana Singh

November 14, 2:48 PM

PDS Biotechnology Corporation (NASDAQ:PDSB) announced updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial. The study is investigating PDS0101…

PDSB

Wells Fargo Downgrades Ulta Beauty to Underweight, Lowers Price Target to $400

By Benzinga Newsdesk

January 6, 8:39 AM

Wells Fargo analyst Ike Boruchow downgrades Ulta Beauty (NASDAQ:ULTA) from Equal-Weight to Underweight and lowers the price target from $450 to $400.

ULTA

Raymond James Maintains Outperform on Murphy USA, Raises Price Target to $300

By Benzinga Newsdesk

July 20, 4:30 AM

Raymond James analyst Bobby Griffin maintains Murphy USA (NYSE:MUSA) with a Outperform and raises the price target from $270 to $300.

MUSA

Goldman Sachs Maintains Neutral on Vontier, Lowers Price Target to $25

By Benzinga Newsdesk

October 11, 9:22 AM

Goldman Sachs analyst Joe Ritchie maintains Vontier (NYSE:VNT) with a Neutral and lowers the price target from $28 to $25.

VNT

Zelman & Assoc Initiates Coverage On Ferguson with Buy Rating

Related Posts

PDS Biotech Posts 100% Clinical Response In Cervical Cancer Patients For Its Lead Program

Wells Fargo Downgrades Ulta Beauty to Underweight, Lowers Price Target to $400

Raymond James Maintains Outperform on Murphy USA, Raises Price Target to $300

Goldman Sachs Maintains Neutral on Vontier, Lowers Price Target to $25